Dr. Konstantin Kousoulas, World’s Most Eminent Virologist Is Named VP of Scientific Affairs at Rational Vaccines

Dr. Konstantin Kousoulas, a leading virologist will work to further Rational Vaccines core mission of eradicating the world of the herpes simplex virus.

“Dr. Kousoulas is one of the world’s most eminent virologists. His work in the field of HSV gives hopes to the millions of patients who are in desperate need of a better standard of care and to all of us who work to defeat this heinous virus,” said Rational Vaccines CEO Agustin Fernandez. “No one understands this virus better than Gus. His addition to the team brings us one step closer to our goal of eradicating the Herpes pandemic.”

Dr. Konstantin Kousoulas is a professor of virology and biotechnology in the Louisiana State University Department of Pathobiological Sciences and director of the Division of Biotechnology and Molecular Medicine (BioMMED).

Dr. Konstantin Kousoulas research focuses primarily on the molecular biology and the immunopathogenesis of human herpes viruses. He has extensively utilized herpes simplex viral vectors for vaccine development and cancer treatment. He has also constructed and patented herpes simplex viruses that have been shown to be highly effective as preventative and therapeutic vaccines for herpes genital and ocular infections, as well as potent adjuvants for cancer immunotherapy, approaches in animal models.

Kousoulas’ work has been published in a variety of scientific publications including the Journals of Veterinary Microbiology and Journal of Virology as well as featured by news outlets around the globe. He received his Master’s and doctorate degrees from Pennsylvania State University in Biophysics and Molecular Cell Biology, respectively. Kousoulas received postdoctoral training under Dr. Bernard Roizman at the University of Chicago and with Dr. Lenore Pereira at the University of California at San Francisco.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”